141 related articles for article (PubMed ID: 11563922)
1. Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.
Schröder J; Henke A; Wenzel H; Brandstetter H; Stammler HG; Stammler A; Pfeiffer WD; Tschesche H
J Med Chem; 2001 Sep; 44(20):3231-43. PubMed ID: 11563922
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.
Cheng M; De B; Pikul S; Almstead NG; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Dowty ME; Mieling GE; Janusz MJ; Wang-Weigand S
J Med Chem; 2000 Feb; 43(3):369-80. PubMed ID: 10669564
[TBL] [Abstract][Full Text] [Related]
3. Novel heterocyclic inhibitors of matrix metalloproteinases: three 6H-1,3,4-thiadiazines.
Schröder J; Wenzel H; Stammler HG; Stammler A; Neumann B; Tschesche H
Acta Crystallogr C; 2001 May; 57(Pt 5):593-6. PubMed ID: 11353263
[TBL] [Abstract][Full Text] [Related]
4. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.
Scozzafava A; Supuran CT
J Med Chem; 2000 Oct; 43(20):3677-87. PubMed ID: 11020282
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
6. The different modes of chiral [1,2,3]triazolo[5,1-b][1,3,4]thiadiazines: crystal packing, conformation investigation and cellular activity.
Obydennov KL; Kalinina TA; Vysokova OA; Slepukhin PA; Pozdina VA; Ulitko MV; Glukhareva TV
Acta Crystallogr C Struct Chem; 2020 Aug; 76(Pt 8):795-809. PubMed ID: 32756043
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors.
Gong YP; Tang LQ; Liu TS; Liu ZP
Molecules; 2019 Nov; 24(23):. PubMed ID: 31775363
[TBL] [Abstract][Full Text] [Related]
8. 2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2lambda6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors.
Apfel C; Banner DW; Bur D; Dietz M; Hubschwerlen C; Locher H; Marlin F; Masciadri R; Pirson W; Stalder H
J Med Chem; 2001 Jun; 44(12):1847-52. PubMed ID: 11384231
[TBL] [Abstract][Full Text] [Related]
9. A novel series of highly selective inhibitors of MMP-3.
Whitlock GA; Dack KN; Dickinson RP; Lewis ML
Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.
Yao W; Wasserman ZR; Chao M; Reddy G; Shi E; Liu RQ; Covington MB; Arner EC; Pratta MA; Tortorella M; Magolda RL; Newton R; Qian M; Ribadeneira MD; Christ D; Wexler RR; Decicco CP
J Med Chem; 2001 Oct; 44(21):3347-50. PubMed ID: 11585439
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of potent and selective aldose reductase inhibitors based on pyridylthiadiazine scaffold.
Chen X; Yang Y; Ma B; Zhang S; He M; Gui D; Hussain S; Jing C; Zhu C; Yu Q; Liu Y
Eur J Med Chem; 2011 May; 46(5):1536-44. PubMed ID: 21367494
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for the highly selective inhibition of MMP-13.
Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
[TBL] [Abstract][Full Text] [Related]
13. Two crystal structures of human neutrophil collagenase, one complexed with a primed- and the other with an unprimed-side inhibitor: implications for drug design.
Gavuzzo E; Pochetti G; Mazza F; Gallina C; Gorini B; D'Alessio S; Pieper M; Tschesche H; Tucker PA
J Med Chem; 2000 Sep; 43(18):3377-85. PubMed ID: 10978185
[TBL] [Abstract][Full Text] [Related]
14. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
[TBL] [Abstract][Full Text] [Related]
15. Investigating chelating sulfonamides and their use in metalloproteinase inhibitors.
Tanakit A; Rouffet M; Martin DP; Cohen SM
Dalton Trans; 2012 Jun; 41(21):6507-15. PubMed ID: 22411188
[TBL] [Abstract][Full Text] [Related]
16. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.
Tamura Y; Watanabe F; Nakatani T; Yasui K; Fuji M; Komurasaki T; Tsuzuki H; Maekawa R; Yoshioka T; Kawada K; Sugita K; Ohtani M
J Med Chem; 1998 Feb; 41(4):640-9. PubMed ID: 9484512
[TBL] [Abstract][Full Text] [Related]
17. Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship.
Matter H; Schudok M; Schwab W; Thorwart W; Barbier D; Billen G; Haase B; Neises B; Weithmann K; Wollmann T
Bioorg Med Chem; 2002 Nov; 10(11):3529-44. PubMed ID: 12213468
[TBL] [Abstract][Full Text] [Related]
18. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates.
Pochetti G; Gavuzzo E; Campestre C; Agamennone M; Tortorella P; Consalvi V; Gallina C; Hiller O; Tschesche H; Tucker PA; Mazza F
J Med Chem; 2006 Feb; 49(3):923-31. PubMed ID: 16451058
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
[TBL] [Abstract][Full Text] [Related]
20. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M
J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
